MUC16 regulates TSPYL5 for lung cancer cell growth and chemoresistance by suppressing p53

Imayavaramban Lakshmanan, Shereen Salfity, Parthasarathy Seshacharyulu, Satyanarayana Rachagani, Abigail Thomas, Srustidhar Das, Prabin D. Majhi, Rama Krishna Nimmakayala, Raghupathy Vengoji, Subodh M Lele, Moorthy Palanimuthu Ponnusamy, Surinder Kumar Batra, Apar Kishor P Ganti

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Purpose: MUC16, a tumor biomarker and cell surface–associated mucin, is overexpressed in various cancers; however, its role in lung cancer pathogenesis is unknown. Here, we have explored the mechanistic role of MUC16 in lung cancer. Experimental Design: To identify the functional role of MUC16, stable knockdown was carried in lung cancer cells with two different shRNAs. Clinical significance of MUC16 was evaluated in lung cancer patient tissues using IHC. We have generated genetically engineered mouse model (KrasG12D; AdCre) to evaluate the preclinical significance of MUC16. Results: MUC16 was overexpressed (P = 0.03) in lung cancer as compared with normal tissues. MUC16 knockdown (KD) in lung cancer cell lines decreased the in vitro growth rate (P < 0.05), migration (P < 0.001), and in vivo tumor growth (P = 0.007), whereas overexpression of MUC16-carboxyl terminal (MUC16-Cter) resulted in increased growth rate (P < 0.001). Transcriptome analysis of MUC16 KD showed a downregulation (P = 0.005) of TSPYL5 gene, which encodes for a testis-specific Y-like protein. Rescue studies via overexpression of MUC16-Cter in MUC16 KD cells showed activation of signaling proteins, such as JAK2 (Y1007/1008), STAT3 (Y705), and glucocorticoid receptor (GR), which constitutes an important axis for the regulation of TSPYL5 for oncogenic process. Further, inhibition of STAT3 (Y705) led to decreased GR and TSPYL5, suggesting that MUC16 regulates TSPYL5 through the JAK2/STAT3/GR axis. Also, MUC16 overexpression induced cisplatin and gemcitabine resistance by downregulation of p53. Conclusions: Our findings indicate a significant role of MUC16 in tumorigenesis and metastasis of lung cancer cells possibly via regulation of TSPYL5 through the JAK2/STAT3/GR axis.

Original languageEnglish (US)
Pages (from-to)3906-3917
Number of pages12
JournalClinical Cancer Research
Volume23
Issue number14
DOIs
StatePublished - Jul 15 2017

Fingerprint

Lung Neoplasms
Glucocorticoid Receptors
Growth
gemcitabine
Down-Regulation
Gene Expression Profiling
Mucins
Tumor Biomarkers
Cisplatin
Testis
Neoplasms
Carcinogenesis
Proteins
Research Design
Neoplasm Metastasis
Cell Line
Genes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

MUC16 regulates TSPYL5 for lung cancer cell growth and chemoresistance by suppressing p53. / Lakshmanan, Imayavaramban; Salfity, Shereen; Seshacharyulu, Parthasarathy; Rachagani, Satyanarayana; Thomas, Abigail; Das, Srustidhar; Majhi, Prabin D.; Nimmakayala, Rama Krishna; Vengoji, Raghupathy; Lele, Subodh M; Palanimuthu Ponnusamy, Moorthy; Batra, Surinder Kumar; Ganti, Apar Kishor P.

In: Clinical Cancer Research, Vol. 23, No. 14, 15.07.2017, p. 3906-3917.

Research output: Contribution to journalArticle

Lakshmanan, Imayavaramban ; Salfity, Shereen ; Seshacharyulu, Parthasarathy ; Rachagani, Satyanarayana ; Thomas, Abigail ; Das, Srustidhar ; Majhi, Prabin D. ; Nimmakayala, Rama Krishna ; Vengoji, Raghupathy ; Lele, Subodh M ; Palanimuthu Ponnusamy, Moorthy ; Batra, Surinder Kumar ; Ganti, Apar Kishor P. / MUC16 regulates TSPYL5 for lung cancer cell growth and chemoresistance by suppressing p53. In: Clinical Cancer Research. 2017 ; Vol. 23, No. 14. pp. 3906-3917.
@article{4c15283ef6c946dfa5479e75da40f201,
title = "MUC16 regulates TSPYL5 for lung cancer cell growth and chemoresistance by suppressing p53",
abstract = "Purpose: MUC16, a tumor biomarker and cell surface–associated mucin, is overexpressed in various cancers; however, its role in lung cancer pathogenesis is unknown. Here, we have explored the mechanistic role of MUC16 in lung cancer. Experimental Design: To identify the functional role of MUC16, stable knockdown was carried in lung cancer cells with two different shRNAs. Clinical significance of MUC16 was evaluated in lung cancer patient tissues using IHC. We have generated genetically engineered mouse model (KrasG12D; AdCre) to evaluate the preclinical significance of MUC16. Results: MUC16 was overexpressed (P = 0.03) in lung cancer as compared with normal tissues. MUC16 knockdown (KD) in lung cancer cell lines decreased the in vitro growth rate (P < 0.05), migration (P < 0.001), and in vivo tumor growth (P = 0.007), whereas overexpression of MUC16-carboxyl terminal (MUC16-Cter) resulted in increased growth rate (P < 0.001). Transcriptome analysis of MUC16 KD showed a downregulation (P = 0.005) of TSPYL5 gene, which encodes for a testis-specific Y-like protein. Rescue studies via overexpression of MUC16-Cter in MUC16 KD cells showed activation of signaling proteins, such as JAK2 (Y1007/1008), STAT3 (Y705), and glucocorticoid receptor (GR), which constitutes an important axis for the regulation of TSPYL5 for oncogenic process. Further, inhibition of STAT3 (Y705) led to decreased GR and TSPYL5, suggesting that MUC16 regulates TSPYL5 through the JAK2/STAT3/GR axis. Also, MUC16 overexpression induced cisplatin and gemcitabine resistance by downregulation of p53. Conclusions: Our findings indicate a significant role of MUC16 in tumorigenesis and metastasis of lung cancer cells possibly via regulation of TSPYL5 through the JAK2/STAT3/GR axis.",
author = "Imayavaramban Lakshmanan and Shereen Salfity and Parthasarathy Seshacharyulu and Satyanarayana Rachagani and Abigail Thomas and Srustidhar Das and Majhi, {Prabin D.} and Nimmakayala, {Rama Krishna} and Raghupathy Vengoji and Lele, {Subodh M} and {Palanimuthu Ponnusamy}, Moorthy and Batra, {Surinder Kumar} and Ganti, {Apar Kishor P}",
year = "2017",
month = "7",
day = "15",
doi = "10.1158/1078-0432.CCR-16-2530",
language = "English (US)",
volume = "23",
pages = "3906--3917",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "14",

}

TY - JOUR

T1 - MUC16 regulates TSPYL5 for lung cancer cell growth and chemoresistance by suppressing p53

AU - Lakshmanan, Imayavaramban

AU - Salfity, Shereen

AU - Seshacharyulu, Parthasarathy

AU - Rachagani, Satyanarayana

AU - Thomas, Abigail

AU - Das, Srustidhar

AU - Majhi, Prabin D.

AU - Nimmakayala, Rama Krishna

AU - Vengoji, Raghupathy

AU - Lele, Subodh M

AU - Palanimuthu Ponnusamy, Moorthy

AU - Batra, Surinder Kumar

AU - Ganti, Apar Kishor P

PY - 2017/7/15

Y1 - 2017/7/15

N2 - Purpose: MUC16, a tumor biomarker and cell surface–associated mucin, is overexpressed in various cancers; however, its role in lung cancer pathogenesis is unknown. Here, we have explored the mechanistic role of MUC16 in lung cancer. Experimental Design: To identify the functional role of MUC16, stable knockdown was carried in lung cancer cells with two different shRNAs. Clinical significance of MUC16 was evaluated in lung cancer patient tissues using IHC. We have generated genetically engineered mouse model (KrasG12D; AdCre) to evaluate the preclinical significance of MUC16. Results: MUC16 was overexpressed (P = 0.03) in lung cancer as compared with normal tissues. MUC16 knockdown (KD) in lung cancer cell lines decreased the in vitro growth rate (P < 0.05), migration (P < 0.001), and in vivo tumor growth (P = 0.007), whereas overexpression of MUC16-carboxyl terminal (MUC16-Cter) resulted in increased growth rate (P < 0.001). Transcriptome analysis of MUC16 KD showed a downregulation (P = 0.005) of TSPYL5 gene, which encodes for a testis-specific Y-like protein. Rescue studies via overexpression of MUC16-Cter in MUC16 KD cells showed activation of signaling proteins, such as JAK2 (Y1007/1008), STAT3 (Y705), and glucocorticoid receptor (GR), which constitutes an important axis for the regulation of TSPYL5 for oncogenic process. Further, inhibition of STAT3 (Y705) led to decreased GR and TSPYL5, suggesting that MUC16 regulates TSPYL5 through the JAK2/STAT3/GR axis. Also, MUC16 overexpression induced cisplatin and gemcitabine resistance by downregulation of p53. Conclusions: Our findings indicate a significant role of MUC16 in tumorigenesis and metastasis of lung cancer cells possibly via regulation of TSPYL5 through the JAK2/STAT3/GR axis.

AB - Purpose: MUC16, a tumor biomarker and cell surface–associated mucin, is overexpressed in various cancers; however, its role in lung cancer pathogenesis is unknown. Here, we have explored the mechanistic role of MUC16 in lung cancer. Experimental Design: To identify the functional role of MUC16, stable knockdown was carried in lung cancer cells with two different shRNAs. Clinical significance of MUC16 was evaluated in lung cancer patient tissues using IHC. We have generated genetically engineered mouse model (KrasG12D; AdCre) to evaluate the preclinical significance of MUC16. Results: MUC16 was overexpressed (P = 0.03) in lung cancer as compared with normal tissues. MUC16 knockdown (KD) in lung cancer cell lines decreased the in vitro growth rate (P < 0.05), migration (P < 0.001), and in vivo tumor growth (P = 0.007), whereas overexpression of MUC16-carboxyl terminal (MUC16-Cter) resulted in increased growth rate (P < 0.001). Transcriptome analysis of MUC16 KD showed a downregulation (P = 0.005) of TSPYL5 gene, which encodes for a testis-specific Y-like protein. Rescue studies via overexpression of MUC16-Cter in MUC16 KD cells showed activation of signaling proteins, such as JAK2 (Y1007/1008), STAT3 (Y705), and glucocorticoid receptor (GR), which constitutes an important axis for the regulation of TSPYL5 for oncogenic process. Further, inhibition of STAT3 (Y705) led to decreased GR and TSPYL5, suggesting that MUC16 regulates TSPYL5 through the JAK2/STAT3/GR axis. Also, MUC16 overexpression induced cisplatin and gemcitabine resistance by downregulation of p53. Conclusions: Our findings indicate a significant role of MUC16 in tumorigenesis and metastasis of lung cancer cells possibly via regulation of TSPYL5 through the JAK2/STAT3/GR axis.

UR - http://www.scopus.com/inward/record.url?scp=85024099643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024099643&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-16-2530

DO - 10.1158/1078-0432.CCR-16-2530

M3 - Article

C2 - 28196872

AN - SCOPUS:85024099643

VL - 23

SP - 3906

EP - 3917

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 14

ER -